- Trial phase
- Phase 1/1b
- Time to market
- 5+ years; still in Phase 1/1b first-in-human testing with no registration-enabling plans announced yet
- Why 6/10
- Preliminary Phase 1 monotherapy data from the BOREALIS-1 trial is expected in H2 2026. This is a dated binary within ~6 months on an asset that is a meaningful but not sole value driver (Erasca also has lead program ERAS-0015 with positive Phase 1 data). Phase 1 readouts typically move stocks 20-50% for early-stage biotechs with robust preclinical data, but the stock's recent run (from ~$1.33 to ~$18) already reflects high expectations.
Watch for Erasca's H2 2026 BOREALIS-1 preliminary data release. ERAS-4001 is a "second shot on goal" after ERAS-0015's strong Phase 1 showing in April 2026. The stock already trades near analyst mean PT of $21 with a massive run-up from 52-week lows, so upside may be partially priced in. The key question is whether early safety/efficacy data can differentiate ERAS-4001 from Revolution Medicines' daraxonrasib (RMC-6236, Phase 3).
Price Chart
Executive Summary
ERAS-4001 is a preclinical-stage-to-Phase 1 oral pan-KRAS inhibitor being developed by Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. In-licensed from Medshine Discovery in 2024, the drug targets the KRAS protein, one of the most important drivers of human cancer, while sparing HRAS and NRAS, which could give it a tolerability edge over broader pan-RAS inhibitors. The BOREALIS-1 Phase 1 trial is actively enrolling, and initial monotherapy data is expected in the second half of 2026. Erasca has a strong cash runway ($408.5M into H2 2028) and deep institutional backing (BlackRock, RTW, Vanguard top holders). However, ERAS-4001 faces intense competition from Revolution Medicines' Phase 3 pan-RAS inhibitor daraxonrasib and approved KRAS G12C drugs from Amgen and BMS/Mirati. The stock has rallied dramatically from $1.33 to ~$18 year-to-date, partially reflecting optimism around the broader pipeline.
How It Works
ERAS-4001 is an oral pill designed to block a cancer-driving protein called KRAS. KRAS is mutated in roughly 25% of all human cancers and acts like a stuck "on" switch that tells cancer cells to grow uncontrollably. Unlike older drugs that target only one specific KRAS mutation (e.g., G12C), ERAS-4001 is a "pan-KRAS" inhibitor, it blocks multiple different mutant forms of KRAS as well as normal (wildtype) KRAS, while purposefully sparing two related proteins HRAS and NRAS. This selectivity is intended to give a wider therapeutic window (fewer side effects) versus broader "pan-RAS" inhibitors.
Trial Status
BOREALIS-1 Phase 1/1b first-in-human trial (NCT07021898) is actively recruiting patients with KRAS-mutant advanced solid tumors. Dose escalation is ongoing as monotherapy, with plans for combination dose-escalation and monotherapy expansion cohorts in 2027. Preliminary Phase 1 monotherapy safety, tolerability, PK, and initial efficacy data expected H2 2026. Preclinical data presented at AACR 2025 showed potent anti-tumor activity with single-digit nanomolar potency against KRAS G12X mutants while sparing HRAS and NRAS.
The Two-Sided Case
Upcoming Catalysts
- Preliminary Phase 1 monotherapy data for ERAS-4001 (BOREALIS-1 trial) expected H2 2026, the next major catalyst
- Monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
- ERAS-0015 (lead program) registration-enabling trial in lung cancer expected H1 2027 and Phase 3 pancreatic cancer trial in 2027, these readouts will also move ERAS stock
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Erasca, Inc. Press Release ERAS ·Originating report